ArticleFrontiers in neuroscience2020
A Ketone Ester Drink Enhances Endurance Exercise Performance in Parkinson's Disease.
Article in Frontiers in neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Pooled it
- Effects of dietary supplements, foods, and dietary patterns in Parkinson's disease: meta-analysis and systematic review of randomized and crossover studies.European journal of clinical nutrition · 2024Pooled it
- Ketogenic interventions in mild cognitive impairment, Alzheimer's disease, and Parkinson's disease: A systematic review and critical appraisal.Frontiers in neurology · 2023Pooled it
- A randomized safety and feasibility crossover trial of two Mediterranean-ketogenic interventions in individuals with Parkinson's disease.Journal of Parkinson's disease · 2026Trial
- Cardiopulmonary responses to acute exogenous ketosis at rest, and during submaximal and maximal exercise.Physiological reports · 2025Trial
- Tolerability and Acceptability of an Exogenous Ketone Monoester and Ketone Monoester/Salt Formulation in Humans.Nutrients · 2023Trial
- Exogenous ketosis in patients with type 2 diabetes: Safety, tolerability and effect on glycaemic control.Endocrinology, diabetes & metabolism · 2021Trial
- The Power of Exercise: Unlocking the Biological Mysteries of Peripheral-Central Crosstalk in Parkinson's Disease.Journal of advanced research · 2025Review
- Healthcare professionals' perception of the ketogenic diet among patients with chronic obstructive pulmonary disease: a cross-sectional study.Frontiers in nutrition · 2025Article
- Signals of energy availability in sleep: consequences of a fat-based metabolism.Frontiers in nutrition · 2024Review
- Molecular mechanism of caloric restriction mimetics-mediated neuroprotection of age-related neurodegenerative diseases: an emerging therapeutic approach.Biogerontology · 2023Review
- Ketogenic diet protects MPTP-induced mouse model of Parkinson's disease via altering gut microbiota and metabolites.MedComm · 2023Article
- Exogenous ketone supplementation: an emerging tool for physiologists with potential as a metabolic therapy.Experimental physiology · 2023Review
- Exogenous Ketone Supplements in Athletic Contexts: Past, Present, and Future.Sports medicine (Auckland, N.Z.) · 2022Review
- Targeting Macroautophagy as a Therapeutic Opportunity to Treat Parkinson's Disease.Frontiers in cell and developmental biology · 2022Review
- Association of decreased triadin expression level with apoptosis of dopaminergic cells in Parkinson's disease mouse model.BMC neuroscience · 2021Article
- Alzheimer's disease alters oligodendrocytic glycolytic and ketolytic gene expression.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2021Article
- Case Report: Ketogenic Diet Is Associated With Improvements in Chronic Obstructive Pulmonary Disease.Frontiers in medicine · 2021Article
- Beta-hydroxybutyrate, an endogenous NLRP3 inflammasome inhibitor, attenuates anxiety-related behavior in a rodent post-traumatic stress disorder model.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
objectivesRoutine exercise is thought to be among the only disease-modifying treatments for Parkinson's disease; however, patients' progressive loss of physical ability limits its application. Therefore, we sought to investigate whether a ketone ester drink, which has previously been shown to enhance endurance exercise performance in elite athletes, could also improve performance in persons with Parkinson's disease.
participants14 patients, aged 40-80 years, with Hoehn and Yahr stage 1-2 Parkinson's disease.
interventionA randomized, placebo-controlled, crossover study in which each participant was administered a ketone ester drink or an isocaloric carbohydrate-based control drink on separate occasions prior to engaging in a steady state cycling test at 80 rpm to assess endurance exercise performance. OUTCOMES MEASURES: The primary outcome variable was length of time participants could sustain a therapeutic 80 rpm cadence. Secondary, metabolic outcomes measures included cardiorespiratory parameters as well as serum β-hydroxybutyrate, glucose, and lactate.
resultsThe ketone ester increased the time that participants were able to sustain an 80 rpm cycling cadence by 24 ± 9% (
conclusionKetone ester supplementation improved endurance exercise performance in persons with Parkinson's disease and may, therefore, be useful as an adjunctive therapy to enhance the effectiveness of exercise treatment for Parkinson's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.